TCM
DNLI icon

Tygh Capital Management’s Denali Therapeutics DNLI Stock Holding History

Tygh Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2.42M Sell
54,226
-109
-0.2% -$5.16K 0.31% 75
2021
Q3 		$2.74M Buy
+54,335
New +$3.06M 0.37% 81

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Tygh Capital Management's DNLI Position: Q4 2021 in Review

Tygh Capital Management reduced its Denali Therapeutics (DNLI) stake by 0.2% in Q4 2021, selling an estimated $5.16K and leaving 54,226 shares worth $2.42M. The position accounts for 0.31% of the portfolio, ranked #75.

Tygh Capital Management first reported a position in DNLI in Q3 2021 and has held it in 2 quarters since. The position peaked at $2.74M in Q3 2021. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

  • Tygh Capital Management held 54,226 shares of Denali Therapeutics worth $2.42M as of Q4 2021.
  • Tygh Capital Management sold 109 Denali Therapeutics shares in Q4 2021, an estimated $5.16K.
  • Denali Therapeutics made up 0.31% of Tygh Capital Management's portfolio in Q4 2021, its #75 holding.
  • Tygh Capital Management first reported a position in Denali Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • Tygh Capital Management's Denali Therapeutics position peaked at $2.74M in Q3 2021.
  • 213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.